Cargando…
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Gene therapy using recombinant adeno‐associated virus (rAAV) vectors to treat blinding retinal dystrophies has become clinical reality. Therapeutically impactful targeting of photoreceptors still relies on subretinal vector delivery, which detaches the retina and harbours substantial risks of collat...
Autores principales: | Pavlou, Marina, Schön, Christian, Occelli, Laurence M, Rossi, Axel, Meumann, Nadja, Boyd, Ryan F, Bartoe, Joshua T, Siedlecki, Jakob, Gerhardt, Maximilian J, Babutzka, Sabrina, Bogedein, Jacqueline, Wagner, Johanna E, Priglinger, Siegfried G, Biel, Martin, Petersen‐Jones, Simon M, Büning, Hildegard, Michalakis, Stylianos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033523/ https://www.ncbi.nlm.nih.gov/pubmed/33616280 http://dx.doi.org/10.15252/emmm.202013392 |
Ejemplares similares
-
Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy
por: Gehrke, Miranda, et al.
Publicado: (2022) -
A Bioengineered In Vitro Model to Assess AAV-Based Gene Therapies for Cyclic GMP-Related Disorders
por: Pavlou, Marina, et al.
Publicado: (2022) -
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
por: Büning, Hildegard, et al.
Publicado: (2019) -
Biology, Pathobiology and Gene Therapy of CNG Channel-Related Retinopathies
por: Gerhardt, Maximilian J., et al.
Publicado: (2023) -
Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
por: Kay, Christine N., et al.
Publicado: (2013)